SGLT2 inhibition in patients with type 2 diabetes and cardiovascular diseases: which are the benefits?
Journal Title: Revista de Medicină Militară - Year 2019, Vol 0, Issue 1
Abstract
Two major trials, EMPA-REG OUTCOME trial (with Empagliflozin) and CANVAS trial (with Canagliflozin) have demonstrated the beneficial effects of SGLT2 inhibitors in patients with type 2 diabetes at risk for heart failure. SGLT2 inhibitors possess a unique pharmacological profile and have shown a significant reduction of hospitalization for heart failure in diabetic patients, immediately after treatment commencement. It seems that their effects are beneficial both in heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. SGLT2 inhibitors reduce cardiovascular endpoints in patients with diabetes and high cardiovascular risk, most likely through a reduction of heart failure-related events. Empagliflozin treatment exerts beneficial effects on vascular function and central haemodynamics. Various mechanisms seem to contribute to the beneficial effects of SGLT2 inhibitors in heart failure. Taking into consideration their cardiovascular benefits and the number of ongoing trials with these drugs, there is a possibility to expand their indication to nondiabetic patients with heart failure. This review focuses on the newest insights into the beneficial effects of SGLT2 inhibitors on the cardiovascular system
Authors and Affiliations
Camelia Diaconu, Teodor Salmen, Mihnea A Gaman, Ovidiu Bratu, Dan Mischianu, D Marcu, Andra I Suceveanu, Raluca S. Costache, Anca Pantea Stoian
Keywords
Related Articles
- EP ID EP481269
- DOI -
- Views 89
- Downloads 0
Ankylosing spondylitis and cardiovascular risk – Case report
Introduction: Ankylosing spondylitis (AS) is a chronic progressive inflammatory disease of the axial skeleton and peripheral joints associated with HLA B27 antigen and with the predominance of the male gender (with an av...
SGLT2 inhibition in patients with type 2 diabetes and cardiovascular diseases: which are the benefits?
Two major trials, EMPA-REG OUTCOME trial (with Empagliflozin) and CANVAS trial (with Canagliflozin) have demonstrated the beneficial effects of SGLT2 inhibitors in patients with type 2 diabetes at risk for heart failure....
Rare case of Stevens-Johnson-TEN overlap syndrome caused by mycotoxins
Mushroom poisoning is rarely associated with skin involvement. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening mucocutaneous reactions, characterized by extensive necrosis. SJS/TE...
Clinical aspects in implant fixed prosthodontics oral rehabilitation. Case report
Benzodiazepine overdose has various clinical manifestation, mainly regarding the central nervous system (CNS), cardiac and respiratory side effects, but rarely results in significant morbidity and mortality. Acute benzod...
Efficacy and safety of Ombitasvir/Paritaprevir/Ritonavir+ Dasabuvir and Ribavirin in patients with compensated HCV cirrhosis
Background and aim: Ombitasvir/Paritaprevir/Ritonavir+Dasabuvir in association with ribavirin was the only interferon-free regimen available in 2015 in Romania for compensated HCV cirrhosis. The aim of our study is to re...